Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00484341|
Recruitment Status : Unknown
Verified October 2015 by MolMed S.p.A..
Recruitment status was: Active, not recruiting
First Posted : June 8, 2007
Last Update Posted : October 9, 2015
Information provided by (Responsible Party):
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||June 2016|
|Estimated Study Completion Date :||June 2017|